Related Experiment Video

Updated: Jun 24, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Steroid effects on ZAP-70 and SYK in relation to apoptosis in poor prognosis chronic lymphocytic leukemia

Jerina Boelens1, Sofie Lust, Femke Van Bockstaele

  • 1Department of Hematology, Ghent University Hospital, Ghent, Belgium. Jerina.Boelens@UGent.be

Leukemia Research
|March 20, 2009
PubMed

Insights

Glucocorticoids (GCs) induce apoptosis in chronic lymphocytic leukemia (CLL) cells, particularly ZAP-70 positive (ZAP-70+) CLL. However, the exact mechanisms driving this increased steroid sensitivity in ZAP-70+ CLL remain elusive.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Glucocorticoids (GCs) are being reconsidered for treating poor-prognosis chronic lymphocytic leukemia (CLL).
  • The precise mechanisms by which GCs induce apoptosis in CLL cells are not fully understood.
  • Methylprednisolone (MP) shows differential effects, inducing apoptosis more readily in ZAP-70 positive (ZAP-70+) CLL compared to ZAP-70 negative (ZAP-70-) CLL.

Purpose of the Study:

  • To investigate the molecular mechanisms underlying the increased sensitivity of ZAP-70+ CLL to glucocorticoids.
  • To explore the role of ZAP-70 and the related tyrosine kinase SYK in GC-induced apoptosis.
  • To elucidate the involvement of protein tyrosine phosphatase 1B (PTP1B) in GC treatment response.

Main Methods:

  • Quantitative analysis of ZAP-70 and SYK expression levels following GC treatment.
  • Assessment of SYK phosphorylation status and PTP1B activity.
  • Pharmacological inhibition of PTP1B to evaluate its impact on ZAP-70 expression, SYK phosphorylation, and GC-induced apoptosis.

Main Results:

  • Glucocorticoid treatment led to the downregulation of both ZAP-70 and SYK in CLL cells.
  • GCs induced the expression and translation of PTP1B, which dephosphorylated SYK.
  • Inhibition of PTP1B restored ZAP-70 expression and SYK phosphorylation but did not affect GC-induced apoptosis.

Conclusions:

  • The downregulation of ZAP-70 and phosphorylated SYK (P-SYK) alone is insufficient to mediate GC-induced apoptosis in CLL.
  • Alternative molecular pathways are responsible for the heightened sensitivity of ZAP-70+ CLL to glucocorticoids.
  • Further research is needed to identify the specific mechanisms driving GC efficacy in ZAP-70+ CLL.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Apoptosis01:30

Apoptosis

Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size reduction of the tissue.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...